Icon
+91 94997 68112
Login Register

Bosulif - (100,500 mg; Tablet, Oral)

Bosutinib Pfizer
100,500 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
 None
Indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Yes
*** ****** *** ******* *** *** ***** ** **** **** ** **** ******* '*** *** **, ****, '*** *** **, **** *** **** ************ *********. ** ****** **** **** *** **** ****** ** *** ****. ***** *** *** ***** **** ** **** '*** (*** **, ****) ** ****** *** *********. *** *** ********* **** ***** **** *** **** *** ***** ****** ********* (*** **, ****). ***** *** ******* ****** ** ********* ** ****** *** ******* ****** ****** ** ******** ****** *** ****. ******* **** ******* ******* *** ****** '*** *** ***** ****** ***** ***-************ ** *** ******. *** ****** *** ********* ******** ****** ********** ** ** ****** ****. ********* *** ****** ** ******** *** *** **** ***********. ***-*** *********** **** ****** ** ******** **, ****. *********, ***** ******** ** *** ****** ****** ** ******* ***** *** ***-*** *********** *** *******, ********* ******** **, ****. ********** ******* **** *******. ******* **** ****** ******* ***** *** **** ***********. *****, ********** ******* **** *** ****** *** *** ****.
Bosulif Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* ******* ******* ******* **** *** *** ********* (***** ******)
*** ****** ******* ******* ******* **** *** *** ********* (***** ******)
*** **** ******* ******* ******* **** *** *** ********* (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** **** **, **** ******* ******** ***** *** **** ***********
*** ****** *** \ *** **** **, **** ******* ********* ******** ****** ** ** ****
*** **** ** \ ** **** *, **** ******* ********* ******** ***** *** **** ***********
  1. *** *, **** : ******* ******** ***** ***** *** **** ** **** ******* '*** *** **, ****, '*** *** **, ****
  2. *** **, **** : *** ****** ******** ***** ***** *** **** ** **** ******* '*** *** **, ****, '*** *** **, ****
  3. *** **, **** : ****** (*****) ***** * **** ******* ******* *** ***.
  4. *** **, **** : *** ******** ***** ***** *** **** ** **** ****** '*** (*** **, ****).
  5. *** *, **** : ***** **** *** ** ** ** ********.
  6. *** **, **** : ********** ********* **** *** ****
  7. *** **, **** : ******* **** *** ******* ******* *** ****** '***.
  8. *** **, **** : *** ****** *** ********* ********. *****://***.**********.***.***/**********_****/*********/****/*****************_***.***
  9. *** *, **** : ***** ******* **** *******, ***** *** ***** ** ********** *** *** *****.
  10. *** *, **** : ***** ******* **** *** ******, ***** *** ***** ** ********** *** *** *****.

Bosulif - (400 mg, tablet, oral)

Bosutinib Pfizer
400 mg, tablet, oral
Less Than $1000 mn
None None
Less Than 5
 None
None None
Indicated for the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML) as well as for chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Yes
******* **** ** *****. *** ********* ***.
Bosulif Patent 1 Patent 2 Patent 3 Patent 4
** *******
*-*******-*-********************** *** *** ********* ** ******* *********** ******** (***) *********** ***** ** *-[(*,*-********-*-*************)*****]-*-*******-*-[*-(*-******-*-***********)*******]-*-********************* *** ******* ** ********* *** **** *-*******-*-********************** *** *** ********* ** ******* *********** ******** (***) *********** *-***************
  1. *** **, **** : * **** ** ** ***** *** ******* ** ******* *** *******

Bosulif - (50MG, 100MG)

Bosutinib None
50MG, 100MG
Less Than $1000 mn
None None
None None
None None
BOSULIF is a kinase inhibitor indicated for the treatment of (1) adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy. (2) Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Yes
Bosulif Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********
*-*******-*-********************** *** *** ********* ** ******* *********** ******** (***) *********** ***** ** *-[(*,*-********-*-*************)*****]-*-*******-*-[*-(*-******-*-***********)*******]-*-********************* *** ******* ** ********* *** **** *********** ***** ** *-[(*,*-********-*-*************)*****]-*-*******-*-[*-(*-******-*-***********)*******]-*-********************* *** ******* ** ********* *** **** *-*******-*-********************** *** *** ********* ** ******* *********** ******** (***) ********* ** ******** ********* ******** ********* ** ******** ********* ********

Bosulif - (50MG, 100MG, 500MG)

Bosutinib None
50MG, 100MG, 500MG
Less Than $1000 mn
None None
None None
None None
BOSULIF is a kinase inhibitor indicated for the treatment of (1) adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy. (2) Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Yes
Bosulif Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********
*-*******-*-********************** *** *** ********* ** ******* *********** ******** (***) *********** ***** ** *-[(*,*-********-*-*************)*****]-*-*******-*-[*-(*-******-*-***********)*******]-*-********************* *** ******* ** ********* *** **** *********** ***** ** *-[(*,*-********-*-*************)*****]-*-*******-*-[*-(*-******-*-***********)*******]-*-********************* *** ******* ** ********* *** **** *-*******-*-********************** *** *** ********* ** ******* *********** ******** (***) ********* ** ******** ********* ******** ********* ** ******** ********* ********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.